C
Regeneron Pharmaceuticals, Inc. REGN
$788.00 $10.001.29%
Recommendation
Hold
Prev Close
$778.00
Volume
1,027,402
Avg Vol (90D)
680,232
Market Cap
$83.70B
Dividend & Yield
--
52-Week Range
$735.95 - $1,211.20
P/E (TTM)
19.25
EPS (TTM)
$40.41
My Lists My Alerts
Report
Rating
Reward
B
Good
Risk
C
Fair
Rating Factors
Growth Index
Fair
Efficiency Index
Excellent
Solvency Index
Excellent
Total Return Index
Fair
Volatility Index
Fair
Dividend Index
--
Headlines
Regeneron Pharmaceuticals Inc (REGN) Showcases Promising Results for Odronextamab in Lymphoma Trials
12/10/2024 - GuruFocus
Regeneron Pharmaceuticals Inc (REGN) Showcases Promising Results for Odronextamab in Lymphoma Trials
12/9/2024 - GuruFocus
Odronextamab ASH Presentations Underscore Impressive Potential in Earlier Lines of Treatment and Additional Types of Lymphoma
12/9/2024 - Globe Newswire
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Position Lifted by Groupama Asset Managment
12/9/2024 - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Nomura Asset Management Co. Ltd.
12/9/2024 - MarketBeat
Kovitz Investment Group Partners LLC Has $3.88 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
12/9/2024 - MarketBeat
Rep. Josh Gottheimer Sells Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock
12/8/2024 - Ticker Report
Rep. Josh Gottheimer Sells Off Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
12/8/2024 - Ticker Report
Regeneron Pharmaceuticals Inc (REGN) Announces Promising Phase 3 Trial Results for Poze-Cemdi ...
12/8/2024 - GuruFocus
Regeneron Pharmaceuticals Inc (REGN) Announces Promising Phase 3 Trial Results for Poze-Cemdi ...
12/8/2024 - GuruFocus
Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab
12/8/2024 - Globe Newswire
Stifel Financial Corp Boosts Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
12/7/2024 - MarketBeat
Polar Asset Management Partners Inc. Sells 900 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
12/7/2024 - MarketBeat
Edgestream Partners L.P. Sells 4,870 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
12/7/2024 - MarketBeat
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
12/6/2024 - PR Newswire
Notable ETF Outflow Detected - VHT, BMY, ELV, REGN
12/6/2024 - ETF Channel
Worldquant Millennium Advisors LLC Makes New $127.49 Million Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
12/6/2024 - MarketBeat
Quantinno Capital Management LP Has $7.86 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
12/6/2024 - MarketBeat
Royal London Asset Management Ltd. Raises Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
12/6/2024 - MarketBeat
Regeneron Pharmaceuticals, Inc. (REGN) Piper Sandler 36th Annual Healthcare Conference (Transcript)
12/5/2024 - SeekingAlpha
Regeneron Pharmaceuticals, Inc. (REGN) Piper Sandler 36th Annual Healthcare Conference (Transcript)
12/5/2024 - Seeking Alpha: Transcripts
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Position Decreased by Janus Henderson Group PLC
12/5/2024 - MarketBeat
Regeneron Pharmaceuticals (REGN, $754.26) RSI Indicator left the oversold zone on December 04, 2024
12/5/2024 - Tickeron - Stocks
Glancy Prongay and Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
12/4/2024 - Globe Newswire
Investment Management Corp of Ontario Has $3.77 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
12/4/2024 - MarketBeat
Income Statement
Total Revenue (TTM)
$13.85B
EBITDA (TTM)
$4.57B
EBIT (TTM)
$4.10B
Net Income (TTM)
$4.65B
Balance Sheet
Total Assets (Q)
$37.44B
Total Debt (Q)
$2.70B
Total Liabilities (Q)
$8.12B
Book Value Per Share (Q)
$272.04
Cash Flow
Cash from Operations (TTM)
$4.25B
Cash from Investing (TTM)
-$2.88B
Cash from Financing (TTM)
-$1.51B
Net Change in Cash (TTM)
-$148.40M
Filings
Filing Date
Thursday, October 31, 2024
Period Date
Monday, September 30, 2024
Next Filing
Week of Feb 3 and 7 (est)
Price History
Loading...
Beta
0.73
7-Day Total Return
4.39%
30-Day Total Return
-15.54%
60-Day Total Return
-31.68%
90-Day Total Return
-27.91%
Year to Date Total Return
-12.93%
1-Year Total Return
-7.20%
2-Year Total Return
3.10%
3-Year Total Return
24.08%
5-Year Total Return
115.52%
52-week Low
Nov 21, 2024 - $735.95
52-week High
Aug 27, 2024 - $1,211.20
Valuation
Market Cap
$83.70B - Large Cap
Enterprise Value
$68.12B
Price/Sales (TTM)
6.53
Price/Book (Q)
2.86
Dividends and Shares
Shares Outstanding
116.20M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.regeneron.com
Phone Number
914 847 7000
Address
777 Old Saw Mill River Road
Tarrytown, NY 10591-6707
Country
United States
Year Founded
1988
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to... more
NASDAQ 12/09/2024 4:00PM Eastern Quotes delayed
Weiss Ratings